Kopran Limited
Financial trend (100/100) does the heavy lifting; quality (47/100) is the drag.
Buy zoneKopran Limited earns a Buy from StocksWizard, with a blended score of 73/100. On 37.4x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. The price is about 8% below its 52-week high of ₹207.28 and 77% above the low of ₹108.04. Financial health scores 35/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 7/9. It clears 9 of 13 investability checks, with durability 47, valuation 74 and momentum 65 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹270.46.
1-year price
EOD · 2026-07-3152-week range
-7.84% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy73Piotroski F-score 7/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 4.9%
- Pass: Low debt (D/E < 0.5): 0.29x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 36%
- Pass: Earnings growing: 95%
- Fail: Net margin ≥ 10%: 3.8%
- Pass: Current ratio > 1.5: 1.51
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 2.39
- Pass: Piotroski ≥ 7: 7/9
Quarterly results
Shareholding
- Promoter50.2%
- Institutions0.2%
- Public & other49.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- High Piotroski quality score (7/9).
Opportunities
- Earnings growing (95% YoY).
- Revenue growing (36% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~77% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (4.9%).
About Kopran Limited
Kopran Limited is an integrated pharmaceutical company that develops, manufactures, and markets active pharmaceutical ingredients and finished dosage forms in India and internationally. The company produces tablets, capsules, syrups, dry powders, suspensions, and injectables in both branded and generic formulations across therapeutic categories including macrolides, antibacterials, anticonvulsants, and antihypertensives.
Kopran Limited — frequently asked questions
Is Kopran Limited a buy, hold or sell?
StocksWizard currently rates Kopran Limited (KOPRAN) a Buy, based on a blended score of 73/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Kopran Limited's fair value?
Our blended DCF and relative-valuation model estimates Kopran Limited's fair value at about ₹338.07, versus a current price of ₹191.03 — roughly 77% upside. On that basis the stock looks undervalued by 77%.
Is Kopran Limited financially healthy?
Kopran Limited scores 35/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 7/9.
How has Kopran Limited's share price performed?
Kopran Limited is up 18% over three months, and last traded at ₹191.03. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.